Table III.
Association of total prediagnostic IgE and the risk of CLL and MM stratified by sex and time to diagnosis
| <20 kU/l | 20–100 kU/l | >100 kU/l | P trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Controls/ cases | ORa | Controls/ cases | ORa (95% CI) | P-value | Controls/ cases | ORa (95% CI) | P | ||
| CLL | |||||||||
| Men | 33/58 | 1.00 | 38/35 | 0.56 (0.26–1.18) | 0.127 | 30/8 | 0.14 (0.05–0.45) | <0.001 | 0.019 |
| Women | 42/55 | 1.00 | 37/25 | 0.52 (0.25–1.07) | 0.076 | 7/5 | 0.40 (0.04–4.15) | 0.442 | 0.473 |
| Cases <3 year after baseline | 24/38 | 1.00 | 21/16 | 0.23 (0.05–1.00) | 0.050 | 12/3 | 0.00 (0.00–0.21) | 0.008 | 0.060 |
| Cases ≥3 year after baseline | 51/75 | 1.00 | 54/44 | 0.54 (0.31–0.94) | 0.030 | 24/10 | 0.21 (0.07–0.63) | 0.005 | 0.044 |
| Cases <5 year after baseline | 39/59 | 1.00 | 36/31 | 0.51 (0.24–1.08) | 0.080 | 20/5 | 0.06 (0.01–0.39) | 0.003 | 0.051 |
| Cases ≥5 year after baseline | 36/54 | 1.00 | 39/29 | 0.53 (0.25–1.10) | 0.086 | 16/8 | 0.28 (0.08–0.97) | 0.044 | 0.195 |
| MM | |||||||||
| Men | 42/54 | 1.00 | 52/54 | 0.79 (0.42–1.50) | 0.473 | 26/12 | 0.37 (0.15–0.94) | 0.036 | 0.443 |
| Women | 53/57 | 1.00 | 39/39 | 0.99 (0.54–1.84) | 0.986 | 13/9 | 0.39 (0.12–1.28) | 0.122 | 0.941 |
| Cases <3 year after baseline | 30/44 | 1.00 | 29/24 | 0.46 (0.21–1.03) | 0.060 | 20/6 | 0.15 (0.04–0.60) | 0.007 | 0.062 |
| Cases ≥3 year after baseline | 65/67 | 1.00 | 41/69 | 1.05 (0.67–1.77) | 0.847 | 24/15 | 0.53 (0.23–1.22) | 0.134 | 0.471 |
| Cases <5 year after baseline | 55/71 | 1.00 | 51/51 | 0.74 (0.42–1.33) | 0.315 | 26/10 | 0.21 (0.08–0.59) | 0.003 | 0.042 |
| Cases ≥5 year after baseline | 40/40 | 1.00 | 40/42 | 0.95 (0.47–1.92) | 0.895 | 13/11 | 0.78 (0.27–2.25) | 0.642 | 0.197 |
aSignificant P-values are indicated in bold. OR and 95% CIs determined by conditional logistic regression. Model based on matching factors and adjusted for smoking status, alcohol consumption at recruitment and highest school level.